AzTrials
AzTrials

Non Small Cell Lung CancerPhase 4PROMETHEENCT06646471

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

A Phase 4 study testing Bio-bank repository, Quality of Life (QoL) and G-Code in people with Non Small Cell Lung Cancer and Lung Cancer, run by GFPC Investigation at 41 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the European Society for Medical Oncology (ESMO). Read more about this study

Who is it for?
Ages 70 years and older
Conditions the study is for
Non Small Cell Lung Cancer, Lung Cancer
What is being tested?
Bio-bank repository, Quality of Life (QoL) and G-Code
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
500 participants
Where
41 sitesFrance
Study dates
26 Sep 2024to 31 Aug 2028
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 70 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Patient ≥70 years
  • Non-small-cell lung cancer for which the multidisciplinary consultation required systemic treatment regardless of Tumor-Node-Metastasis (TNM) stage
  • Patient naïve to systemic anticancer treatment for bronchial neoplasia
  • Patient covered by social security
  • Patient eligible for systemic treatment
  • Systemic treatment with marketing authorization in the indication, available in routine care early access or compassionate access.
Show all 9Show fewer
  • Patient able to understand the protocol
  • Patient not opposed to the collection of data concerning him/her
  • Signature of study consent form.

Who cannot join

  • Patients under guardians or curators
  • Patient not under the care of the investigating center and not monitored by the investigating center
  • Patient already treated with systemic therapy for NSCLC

Trial locations and contacts

41 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Romain CORRE, Medical Doctor contact

+330298526404

romain.corre@ch-cornouaille.fr

41 sites in 1 country

France41 sites, 41 recruiting
  • CH du Pays d Aix

    Aix-en-Provence, 13616

    Stéphanie MARTINEZ, smartinez@ch-aix.fr

    Recruiting
  • Hôpital Henri Duffaut

    Avignon, 84000

    Nicolas CLOAREC, clarec.nicolas@ch-avignon.fr

    Recruiting
  • Institut du Cancer d'Avignon

    Avignon, 84918

    Magali RAVOIRE, m.ravoire@isc84.org

    Recruiting
  • CH Bastia

    Bastia, 20600

    Pascal THOMAS, pascal.thomas@ch-bastia.fr

    Not yet recruiting
  • Oncologie Thoracique Hôpital Morvan

    Brest, 29200

    Renaud DESCOURT, renaud.descourt@chu-brest.fr

    Recruiting
  • Pneumologie Centre François Baclesse

    Caen, 14000

    Hubert CURCIO, h.curcio@baclesse.unicncer.fr

    Not yet recruiting
  • CH Métropole-Savoie

    Chambéry, 73000

    Julian PINSOLLE, julian.pinsolle@ch-metropole-savoie.fr

    Recruiting
  • Centre Hospitalier du Cotentin

    Cherbourg, 50102

    Laure KALUZINSKI, l.kaluzinski@ch-cotentin.fr

    Recruiting
  • CHU Hôpital Montpied

    Clermont-Ferrand, 63000

    Patrick MERLE, pmerle@chu-clermontferrand.fr

    Not yet recruiting
  • Pneumologie Hospices Civils de Colmar

    Colmar, 68024

    Lionel MOREAU, lionel.moreau@ch-colmar.fr

    Recruiting
  • Pneumologie CHI Creteil

    Créteil, 94010

    Isabelle MONNET, isabelle.monnet@chicreteil.fr

    Recruiting
  • CH Elbeuf

    Elbeuf, 76503

    Pierre Alexandre HAUSS, Pierre-Alexandre.Hauss@chi-elbeuf-louviers.fr

    Recruiting
  • Polyclinique de Blois

    La Chaussée-Saint-Victor, 41260

    Philippe LAPLAIGE, dr.laplaige@wanadoo.fr

    Not yet recruiting
  • CHD Les Oudairies

    La Roche-sur-Yon, 85000

    Acya BIZIEUX, acya.bizieux@ght85.fr

    Recruiting
  • CH La Rochelle

    La Rochelle, 17000

    Marion LAFARGE, marion.lafarge@ght-atlantique17.fr

    Recruiting
  • Hôpital A. Mignot

    Le Chesnay, 78157

    Cécile DUJON, Cdujon@ght78sud.fr

    Recruiting
  • Hôpital Robert Boulin

    Libourne, 33505

    Samir ABDICHE, menouar-samir.abdiche@ch-libourne.fr

    Recruiting
  • CHU Dupuytren

    Limoges, 87042

    Yannick SIMONNEAU, yannick.simonneau@chu-limoges.fr

    Recruiting
  • Hôpital de la Vallée - Service Pneumologie

    Longjumeau, 91160

    Alain BAKEBE, a.bakebe@gh-nord-essonne.fr

    Recruiting
  • Centre Léon Bérard

    Lyon, 69373

    Chantal DECROISETTE, chantal.decroisette@lyon.unicancer.fr

    Recruiting
  • Hôpital Européen de Marseille

    Marseille, 13003

    Jacques LE TREUT, j.letreut@hopital-europeen.fr

    Recruiting
  • Oncologie Thoracique Hôpital Nord

    Marseille, 13915

    Laurent GREILLIER, laurent.greillier@ap-hm.fr

    Recruiting
  • GHEF Site de Meaux

    Meaux, 77100

    Chrystèle LOCHER, chlocher@ghef.fr

    Recruiting
  • Centre d Oncologie de Gentilly

    Nancy, 54000

    Laurene GAVOILLE, L.gavoille@oncog.fr

    Recruiting
  • Pneumologie CHR

    Orléans, 45067

    Hugues MOREL, hugues.morel@chr-orleans.fr

    Recruiting
  • Pneumologie Hôpital Cochin

    Paris, 75014

    Marie WISLEZ, marie.wislez@aphp.fr

    Not yet recruiting
  • Pneumologie Hôpital Tenon

    Paris, 75970

    Constance METEYE, constance.meteye@aphp.fr

    Not yet recruiting
  • Cantre Catalan d Oncologie

    Perpignan, 66000

    Sabine VIEILLOT, sabinevieillot@gmail.com

    Not yet recruiting
  • CH Annecy Genevois

    Pringy, 74374

    Emilie PLUQUET, epluquet@ch-annecygenevois.fr

    Recruiting
  • Pneumologie CHI Quimper

    Quimper, 29000

    Romain CORRE, romain.corre@ch-cornouaille.fr

    Recruiting
  • CHU Hôpital Ponchailloux

    Rennes, 35033

    Charles RICORDEL, charles.ricordel@chu-rennes.fr

    Recruiting
  • Pneumologie Hôpital Charles Nicolle

    Rouen, 76031

    Florian GUISIER, florian.guisier@chu-rouen.fr

    Not yet recruiting
  • Pneumologie CHU Felix Guyon

    Saint-Denis, 97400

    Diane MOREAU, diane.moreau@chu-reunion.fr

    Recruiting
  • Pneumologie CHU St Etienne

    Saint-Etienne, 42270

    Sophie BAYLE-BLEUEZ, sophie.bayle@chu-st-etienne.fr

    Recruiting
  • Clinique Mutualiste

    Saint-Nazaire, 44600

    Thierry CHATELLIER, thierry.chatellier@hospigrandouest.fr

    Recruiting
  • CHU de la Réunion

    Saint-Pierre, 97410

    Eric HUCHOT, eric.huchot@chu-reunion.fr

    Recruiting
  • CLCC Paul Strauss

    Strasbourg, 67000

    Roland SCHOTT, r.schott@icans.eu

    Recruiting
  • Hôpital d'Instruction des Armées Saint-Anne

    Toulon, 83041

    Olivier BYLICKI, bylicki.olivier@yahoo.fr

    Recruiting
  • CHITS Toulon Sainte Musse

    Toulon, 83056

    Clarisse AUDIGIER VALETTE, clarisse.audigier-valette@ch-toulon.fr

    Recruiting
  • Oncologie CHBA

    Vannes, 56000

    Gonzague DE CHABOT, gonzague.dechabot@ch-bretagne-atlantique.fr

    Recruiting
  • Hôpital Nord OUest

    Villefranche-sur-Saône, 69655

    Lionel FALCHERO, LFalchero@lhopitalnordouest.fr

    Recruiting

Other trials in France

About this study

Official title: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly

The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the European Society for Medical Oncology (ESMO). This cohort will aim to:

  • characterize participants in terms of geriatrics, biology and carcinology
  • describe the treatment modalities by stage, as well as the results in terms of efficacy, safety and impact on quality of life.
Read more

At the same time, exploratory sub-cohorts will be identified including participants treated uniformly with the same molecule, and/or the same innovative strategy.

Participants will be followed in accordance with investigator's usual clinical practice at the corresponding site. They will be asked to:

  • visit the clinic as per physician's request for checkups and tests for assessing general condition and clinical efficacy and tolerance of current treatment.
  • perform the necessary regular para-clinical examinations (lab testing, imaging, re-biopsy).
  • provide blood samples for bio-bank repository
  • perform assessments specific to older adults
  • answer three quality of life questionnaires
Being tested
Bio-bank repository, Quality of Life (QoL), G-Code
Medical subject headings
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bio-bank repositoryGenetic

    Blood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years

  • Quality of Life (QoL)Other

    Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14:

    • stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression.
    • operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months.
    • radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months.
  • G-CodeProcedure or surgery

    G-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment.

Study groups in NCT06646471
Study groupRoleWhat they receive
Real world cohort of NSCLC older adults patientsOtherCohort of patients ≥70 years of age with NSCLC treated in first line therapy for thoracic tumors according to ESMO-referenced therapeutic standards or according to an innovative molecule and/or strategy. An optional biobank based on blood samples taken during the screening phase prior to the first administration of systemic treatment will be collected. Sampling of tumoral materials will be collected prior to study participation and send for central reading. Patients will be asked to come at the hospital for their regular visits as per site current practice and to complete three quality of life questionnaires (EORTC QLQ-F17; QLQ-LC13; QLQ-ELD14).
Receives: Genetic: Bio-bank repository; Other: Quality of Life (QoL); Procedure: G-Code

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression Free Survival (PFS)

    The Progression Free Survival is defined as the time between treatment start date and event date defined by the Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 progression or death for any cause, whichever comes first.

    Disease progression will be evaluated according to (RECIST) 1.1 assessed locally. Frequency of this assessment is let to the investigator \'s discretion and local practices.

    The participants will be followed until disease progression or death for any cause. Patients without an event at the time of analysis will be censored at the date of their last tumor assessment.

    Measured: From the date of first dose of treatment received until the date of the first documented disease progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 or to death from any cause, whichever comes first, assessed up to 2 years

Secondary outcomes (16)
  1. Objective Response Rate (ORR)

    The objective response rate (ORR) is defined as the proportion of patients with complete response (CR) or partial response (PR) as the best response during the study according to RECIST 1.1 criteria based on tumoral assessment performed by thorax-abdominal-pelvic and brain CT scans. The frequency of the tumor assessments will follow the site practices.

    Measured: From the date of first dose of treatment received until the date of the first documented disease progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 or to death from any cause, whichever comes first, assessed up to 2 years

  2. Overall Survival (OS)

    Overall survival (OS) is calculated as the time between the date of treatment initiation and date of death, and censored at date of last news for patients alive at the end of the study.

    Measured: From the treatment start date up to the date of death for a 2-year-period maximum

  3. Duration of Response (DOR)

    The duration of response is defined as the time between the date of the first response assessed by RECIST 1.1 to the date of progression or death for any cause, whichever comes first, and censored at the date of last tumor evaluation for patients still responding to treatment at the end of the study (after 2 years).

    Measured: From the date of the first response to the date of progression or death, whichever comes first, or for a 2-year-period maximum

  4. Time to Response (TTR)

    Time to response is measured from the date of treatment initiation to the date of first response as defined by RECIST 1.1.

    Measured: From the start date of treatment up to the date of first response or for a 2-year-period maximum

  5. Treatment Duration

    The duration of treatment is defined as the time between the treatment start date and the date of definitive cessation of treatment, whatever the cause.

    Measured: From the treatment start date and the treatment stop date whatever the cause up to a 2-year-period maximum.

  6. Safety events

    All adverse events experienced by the participants, whatever the grades of toxicity, will be collected according to CTCAE v4.0 (common terminology criteria for adverse events).

    Measured: From the enrollment up to the participants study end date or for a 2-year-period maximum

  7. Treatments description

    The treatments for NSCLC will be described including the adaptations: discontinuations, treatment interruptions, dose adaptations. The reasons for the changes will be recorded.

    Measured: From the start date of the NSCLC treatment up to the participant study end date or for a 2-year-period maximum

  8. Geriatric interventions: specialized consultations

    The specialized geriatric consultations carried out to correct frailties will be collected during the study participation including psychological and/or dietetic consultations.

    Measured: From the enrollment up to the participant study end date or for a 2-year-period maximum

  9. Geriatric interventions: specialized exercises

    The specialized geriatric exercises carried out to correct frailties will be collected during the study participation including prescription of adapted physical activity and/or cognitive stimulation exercises.

    Measured: From the enrollment up to the participant study end date or for a 2-year-period maximum

  10. Geriatric interventions: specialized help at home

    The specialized geriatric interventions at home carried out to correct frailties will be collected during the study participation including home visits by a nurse or home help.

    Measured: From the enrollment up to the participant study end date or for a 2-year-period maximum

  11. Geriatric interventions: specialized medications

    The specialized geriatric medications carried out to correct frailties will be collected during the study participation.

    Measured: From the enrollment up to the participant study end date or for a 2-year-period maximum

  12. European Organisation for Research and Treatment of Cancer Core Function Questionnaire (QLQ-F17)

    The QLQ-F17 is a validated cancer-specific questionnaire specific to cancer. It includes 17 items to assess 6 QoL scales: 1 global health scale and 5 functional scales (physical, role,emotional, cognitive, social). This is a shortened version of the QLQ-C30, containing only the functional and overall quality of life sections. This questionnaire was developed by the EORTC in order to optimize the collection of quality-of-life data, and to avoid overloading the patient with a lengthy questionnaire.

    Symptoms will be assessed via modules. A score is generated for each dimension and standardized on a scale from 0 to 100, so that a high score reflects a high overall health status, a high functional level and a high symptomatic level. According to EORTC recommendations, the score can be calculated if at least 50% of the items in the corresponding dimension have been completed. Otherwise, the score will be considered missing.

    Measured: At enrolment, at 12 weeks, at 6 months and at 12 months.

  13. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-ELDerly 14 (QLQ-ELD14)

    The QLQ-ELD14 questionnaire is specific to elderly cancer patients. It contains 14 items measuring 7 dimensions of quality of life : two functional dimensions (maintaining a positive positive vision/motivation, family support) and 5 symptomatic dimensions (mobility, worries about others, worries about the future, disease burden, joint problems).

    All of the scales and single-item range in score from 0-100. A score is generated for each dimension, so that a high score reflects a high functional level (for the scales concerned), and a high symptomatic level (for the scales concerned).

    Measured: At enrolment, at 12 weeks, at 6 months and at 12 months

  14. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)

    The QLQ-LC13 is a lung cancer-specific questionnaire containing 13 items to assess symptoms specific to lung cancer and its treatment: dyspnea, cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm or shoulder pain or shoulder pain, pain in other parts, anti-inflammatory drugs, drugs for pain. A score is generated per dimension so that a high score reflects a high symptomatic level.

    All of the scales and single-item range in score from 0-100. A high scale score represents a higher response level.

    Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status represents a high quality of life, but a high score for symptom scale/item represents a high level of symptomatology/problems.

    Measured: At enrolment, at 12 weeks, at 6 months and at 12 months

  15. Geriatric characteristics G8 score

    The following geriatric characteristics will be collected is available in the participant medical file: G8 score.

    The total G-8 score lies between 0 and 17. A higher score indicates a better health status.

    Measured: At enrollment and at disease progression for a maximum of 2-year-period.

  16. Geriatric characteristics Geriatric Core DatasEt (G-CODE)

    The following geriatric characteristics will be collected is available in the participant medical file: Geriatric Core DatasEt (G-CODE). G-CODE is a core set of geriatric data. It has ten tools/items and a median completion time of 9 min. It includes Katz autonomy scale (ADL), Instrumental Activities of Daily Living (IADL), Charlson score, mini Geriatric Depression Sale (mini-GDS), short cognitive impairment screening exam (mini COG), falls history, Timed Get Up and Go test, social environment.

    The G-CODE allows for a minimal geriatric description of the older cancer population and standardisation of geriatric data, enabling comparison across trials.

    Measured: At enrollment and at disease progression for a maximum of 2-year-period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Oct 2024
  2. Study start26 Sep 2024
  3. Primary completion31 Aug 2026 (estimated)
  4. Study completion31 Aug 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06646471
Sponsor's protocol ID
GFPC 05-2023
Acronym
PROMETHEE
Status last verified
Apr 2026
First submitted
27 Sep 2024
Last updated
29 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Bio-bank repository, Quality of Life (QoL) and G-Code in people with Non Small Cell Lung Cancer and Lung Cancer, run by GFPC Investigation at 41 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 41 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Romain CORRE, Medical Doctor (+330298526404, romain.corre@ch-cornouaille.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression Free Survival (PFS) (time frame: From the date of first dose of treatment received until the date of the first documented disease progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 or to death from any cause, whichever comes first, assessed up to 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in